The Effects of Hepatogomax Enteral Formula on Systemic Inflammation, Caecum Short-Chain Fatty Acid Levels, and Liver Histopathology in Thioacetamide-Induced Rats

Purnomo, Hery D. and Kusuma, Refani A. and Sianturi, Elfrida and Haroen, Ryan F. and Solichin, Muchamad R. and Nissa, Choirun and Pramono, Adriyan and Mahati, Endang and Noer, Etika R. (2023) The Effects of Hepatogomax Enteral Formula on Systemic Inflammation, Caecum Short-Chain Fatty Acid Levels, and Liver Histopathology in Thioacetamide-Induced Rats. Journal of Nutrition and Metabolism, 2023: 2313503. pp. 1-9. ISSN 20900724

[thumbnail of 458_Hery D Purnomo.pdf] Text
458_Hery D Purnomo.pdf - Published Version
Restricted to Registered users only
Available under License Creative Commons Attribution.

Download (1MB) | Request a copy

Abstract

Liver damage characterized by fibrosis and necrosis can worsen the condition of liver disease. Liver disease is associated with impaired immune response and may affect short-chain fatty acid (SCFA) gut metabolites. Hepatogomax enteral formula was developed, which contains brain-chain amino acids (BCAAs) and middle-chain triglycerides (MCTs), which could repair liver tissue damage, improve the inflammatory status, and modulate SCFA in liver damage. The study aimed to determine the effect of hepatogomax on liver tissue repair, inflammation (TNF-α and IL-6), and SCFA levels in thioacetamide (TAA)-induced rats. The induction of TAA causes liver steatosis, increasing TNF-α and IL-6, and decreasing SCFA levels. Hepatogomax at a dose of 14.6 g/200 gBW significantly reduces TNF-α and IL-6 levels and increases SCFA levels (p < 0.05). The number of steatosis between groups P2 and P3 was lower as compared to a group of negative control K2 (p < 0.05). Hepatogomax, in a dose-dependent manner, may repair liver tissue and improve inflammatory response and SCFA levels in TAA-induced rats. © 2023 Hery D. Purnomo et al.

Item Type: Article
Additional Information: Cited by: 0; All Open Access, Gold Open Access, Green Open Access
Uncontrolled Keywords: hepatogomax enteral formula; interleukin 6; liver protective agent; short chain fatty acid; thioacetamide; tumor necrosis factor; unclassified drug; adult; animal experiment; animal model; animal tissue; Article; body weight; controlled study; fatty liver; hepatitis; histopathology; liver tissue; male; nonhuman; rat
Subjects: R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
R Medicine > RB Pathology
Divisions: Faculty of Medicine, Public Health and Nursing > Public Health and Nutrition
Depositing User: Ngesti Gandini
Date Deposited: 16 Aug 2024 00:47
Last Modified: 16 Aug 2024 00:47
URI: https://ir.lib.ugm.ac.id/id/eprint/2793

Actions (login required)

View Item
View Item